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Abstract
To systematically review the current literature investigating associations between zinc-alpha2-glycoprotein (ZAG) and dysglycaemia
(including type 2 diabetes (T2DM), poly-cystic-ovary syndrome (PCOS), pre-diabetes or insulin resistance). This included relation-
ships between ZAG and continuousmeasures of insulin and glucose. Additionally, we performed ameta-analysis to estimate the extent
that ZAGdiffers between individualswith orwithout dysglycaemia;whilst examining the potential influence of adiposity. A systematic
search was performed on four databases for studies on circulating ZAG concentrations in adult human populations, comparing healthy
controls to individuals with dysglycaemia. Key characteristics, including themean ZAG concentrations (mg∙L−1), and any correlational
statistics between ZAG and continuous measures of glucose, glycated haemoglobin (HbA1c) or insulin were extracted. Meta-analyses
were performed to compare metabolically healthy controls to cases, and on studies that compared controls and cases considered
overweight or obese (body mass index (BMI) ≥25 kg.m2). 1575 papers were identified and 14 studies (16 cohorts) were considered
eligible for inclusion. Circulating ZAGwas lower in individuals with dysglycaemia compared to metabolically healthy controls (−4.14
[−8.17, −0.11] mg.L−1; I2 = 98.5%; p < 0.001). When using data from only studies with overweight or obese groups with or without
dysglycaemia (three studies (four cohorts); pooled n = 332), the difference in circulating ZAGwas no longer significant (−0.30 [−3.67,
3.07] mg. L−1; I2 = 28.0%; p = 0.225). These data suggest that ZAGmay be implicated in dysglycaemia, although there was significant
heterogeneity across different studies and the mediating effect of adiposity cannot be excluded. Therefore, more research is needed
before robust conclusions can be drawn.
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1 Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease
characterised by peripheral insulin resistance (IR) and inadequate
relative insulin secretion, resulting in hyperglycaemia (1). T2DM
encompasses approximately 90% of all cases of diabetes, with
the worldwide prevalence of diabetes expected to rise from 415
million (2015) to 642 million by 2040, equivalent to more than
5% of the world’s population (2).
Excess adipose tissue, as seen in obesity, plays a central
role in promoting IR and increasing the risk of developing
T2DM. Adipose tissue acts as a powerful endocrine organ
secreting a range of cytokines (termed adipokines) that affect
whole-body physiology (3). Ectopic fat is associated with el-
evated levels of pro-inflammatory adipokines (e.g. tumour-
necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and
leptin) and lower levels of anti-inflammatory adipokines
(e.g. adiponectin) which have been postulated to contribute
to the development of IR and T2DM (4–7).
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One adipokine that has come under recent scrutiny for
its association with T2DM is Zinc-alpha2-glycoprotein
(ZAG). ZAG is a 40–43 kDa single chain polypeptide
(8) that is typically found in the majority of body fluids.
Due to ZAG’s presence in a high number of body com-
ponents, it has been suggested to play many roles in the
body, including: fertilization, ribonuclease activity, cell
adhesion, the regulation of melanin production, hindering
tumour proliferation and promoting lipolysis (the hydro-
lysis of lipids into non-esterified fatty acids) (8). ZAG
acts as an initiator of the catalytic conversion of adeno-
sine triphosphate to cyclic adenosine monophosphate (c-
AMP), which is the initial step of lipolysis (9) by binding
to beta-3-adrenoreceptors on adipocyte surfaces. For this
reason, ZAG has recently been categorised as a lipid-
mobilising factor (10).
Although ZAG has been identified as an adipokine, its
physiological effects on the risk and development of
obesity-related diseases has not been fully determined.
Findings have indicated that increased macrophage infil-
tration and the subsequent release of inflammatory cyto-
kines, including TNF-alpha and IL-6, supresses ZAG re-
lease (11), which could be a contributor to reduced lipol-
ysis and greater levels of ectopic fat. In line with these
findings, ZAG has been shown to be positively associated
with adiponectin (12, 13).
Expanding upon this evidence, elevated ZAG concentra-
tions have been observed in cancer cachexia (14, 15), which
could be a result of increased glucocorticoid levels (16).
However, cancer cachexia has been associated with increased
IR (17), which suggests a complex interaction of inflammato-
ry markers.
The expanding evidence demonstrating the role of
ZAG in lipid and glucose homeostasis has led to ZAG
becoming a protein of increasing interest for anti-obesity
and obesity-related disease therapy (18). In particular,
lower levels of ZAG have been reported to be associated
with the development and severity of T2DM, however the
literature is contradictory, and no summary evidence has
been published to date to quantify the magnitude of the
association. This study aims to systematically review the
current literature investigating the association between
ZAG and metabolic dysfunction, identified as chronic dis-
eases or conditions classified by hyperglycaemia or IR,
referred to as dysglycaemia from here on. This includes
reporting on the relationship between ZAG, insulin and
glucose. Additionally, a meta-analysis will estimate the
extent to which ZAG differs between individuals with or
without dysglycaemia. In order to examine the potential
influence of adiposity, the meta-analysis will also be re-




This systematic review was designed according to National
Institute for Health and Care Excellence (NICE) Systematic
Review guidelines (19) and British Medical Journal checklist
(20). The basis for this review was developed using the PICO
model (presented in detail within Supplementary Materials
Section 3: PICO Model Interpretation). Observational studies
reporting associations between circulating ZAG concentra-
tions (based on targeted assay analyses) and T2DM or other
forms of dysglycaemia (e.g. pre-diabetes, polycystic ovary
syndrome (PCOS), IR without diabetes and metabolic syn-
drome (MetS)), including a comparison with circulating
ZAG concentrations in metabolically healthy individuals,
were retrieved from four electronic databases (PubMed,
Medline, Web of Science and Scopus). The inclusion of
PCOS as a form of dysglycaemia in this study is due to the
higher level of IR, and increased risk of pre-diabetes and
T2DM when compared to the general population (21, 22).
The search strategy combined keywords related to ZAG and
T2DM (including common terms for dysglycaemia)
(Supplementary Materials Section 3: Key words). There was
no date restriction placed on the database search, but all papers
must have been written in English or translated into English.
Full inclusion criteria and detailed search strategy are located
in Supplementary Materials (Section 3: Inclusion criteria and
Selection process). Reference lists of retrieved articles were
manually scanned for additional eligible studies. All aspects
of literature search and study selection were performed by two
researchers independently (HMP and JH).
2.2 Data extraction
Data extraction was performed by two independent re-
viewers (HMP and JH). Extracted data included: descrip-
tive information of the study (first author, date and coun-
try performed in) and participant characteristics (number
of cases and controls, age and body mass index (BMI)).
Data on correlational statistics for the association between
ZAG and continuous measures of glucose, glycated
haemoglobin (HbA1c) and insulin were also extracted.
ZAG mean concentration for the groups (mg. L−1), the
standard deviation (SD) for the ZAG mean and the group
sizes were taken for both the controls and cases from the
least adjusted results. This allowed the raw mean differ-
ence between cases and controls to be calculated in order
to conduct the meta-analysis. Further information on the
data extraction process can be found in the Supplementary
Materials (Section 3: Data extraction).
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2.3 Assessing risk of bias
The risk of bias assessment for studies included in this review
was performed by two reviewers independently (HMP and
JH) using the Strengthing the reporting of observational stud-
ies in epidemiology (STROBE) tool (23). Consensus was
reached for each study with, if necessary, consultation of a
third reviewer (TEY). Publication bias was assessed using
funnel plots. Publication bias is important to consider as the
reporting of null results can often be neglected and only results
considered significant are put in to publication, which can lead
to detrimental conclusions (24, 25).
2.4 Meta-analysis
Pooled mean difference with 95% confidence intervals [95%
CI] was calculated between cases and controls for circulating
ZAG concentrations, using random effects models. The per-
centage of variability across studies attributable to het-
erogeneity beyond chance was quantitatively assessed
using the I2 statistic (0% inferring no observed hetero-
geneity, 25% low heterogeneity, 50% medium heteroge-
neity and ≥ 75% infers high heterogeneity) (25). The
meta-analysis was presented with data further separated
into subgroups to explore pooled effects within T2DM,
PCOS and “other” forms of dysglycaemia (MetS, pre-
diabetes or IR without diabetes).
To mediate the effects of adiposity on the difference in
ZAG between groups, a sensitivity analysis was performed
by conducting a meta-analysis on the models that allowed
for comparisons in overweight or obese groups. The criteria
for inclusion in this restricted meta-analysis are located in the
Supplementary Material (Section 3: Data extraction).
2.5 Narrative review
A narrative review of the extracted correlational statistics
(Supplementary Materials Section 2: Fig. 3) between circulat-
ing ZAG concentration and circulating markers of glucose
(fasting glucose (FG), 2-h or random glucose (2 h/RG),
glycated haemoglobin (HbA1c)) and insulin (fasting insulin
(FIns) and homeostatic model assessment of insulin (HOMA-
IR)) was performed using data from the least adjusted models.
Meta-analyses were not performed due to many studies
reporting incomplete data, such as presentation of p-values
without the corresponding correlation coefficients. For ease
of identification, each included study is referred to by a study
number (SN). The full study titles and corresponding SN is
located in the Supplementary Material (Section 1: Study
numbers).
2.6 Statistical analysis
A p value of <0.05 was considered statistically significant.
Quantitative analysis was conducted using commercially
available software STATA 15.0 (STATA, Version 15.0,
StataCorp, College Station, Texas, USA).
3 Results
3.1 Systematic review
1575 studies were identified, of which 14 (16 cohorts) were
included in the present review (publication dates spanning
from 2008 to 2019)(13, 26–38). Further detail of the study
selection process can be seen in supplementary materials
(Supplementary Materials Section 2: Fig. 1). In total, 3127
participants were included across all studies, which included
studies from China (Study number (SN) =1, 3, 4, 5, 10, 11, 12
and 13), Spain (SN = 6, 7 and 9), Czech Republic (SN = 2),
Slovakia (SN = 8) and Egypt (SN = 14). Two studies (SN = 8
and 11) included data from more than one cohort within the
same publication, whilst one study (SN = 3) allowed for data
from one control group to be compared to three dysglycaemic
groups (PCOS, impaired glucose tolerance and T2DM). All
studies quantified ZAG using enzyme-linked immunosrobent
assays (ELISA). Only two studies included in this study were
prospective cohort studies (SN = 10 and 13), whilst all others
were cross sectional analyses. Participants were either recruit-
ed as cases versus controls (SN = 1, 2, 3, 4, 5 and 13) or as
whole cohorts which were then categorised after recruitment
(SN = 6, 7, 8, 9, 10, 11, 12 and 14). Individual study sample
sizes ranged from 24 (SN = 8) to 489 individuals (SN = 1). Of
the studies that reported these variables, the mean (±SD) age
of the individuals recruited ranged from 25.6 ± 2.2 (SN = 4) to
77.2 ± 6.1 (SN = 10) years and the mean BMI ranged from
20.50 ± 2.70 (SN = 4) to 57.32 ± 5.95 (SN = 7) kg·m2 across
the studies. Full details of all the included studies can be found
in the Supplementary Materials (Section 2: Table 1).
3.2 Risk of bias assessment
A STROBE risk of bias assessment, performed by two re-
viewers independently, identified that two studies were of
low quality (SN = 2 and 8), 10 were of medium quality
(SN = 1, 3, 4, 5, 6, 9, 10, 12, 13 and 14) and two were of high
quality (SN = 7 and 11). Common aspects were: lack of
reporting on how the sample size was determined or how
participants were recruited. Risk of bias for participant selec-
tion was detected in SN = 6, 7 and 8. Full details of included
studies can be found in Supplementary Table 1. The funnel
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plots (Supplementary Material Section 2: Fig. 4 a & b), show
no significant publication bias for the cohort as a whole but
significant bias was identified when reporting only the over-
weight and obese individuals (p < 0.001).
3.3 Meta-analysis
3.3.1 Absolute pooled data
When data were pooled, circulating ZAG concentrations were
lower in those with dysglycaemia compared to metabolically
healthy controls (−4.14 [−8.17, −0.11] mg. L−1)
(Supplementary Materials Section 2: Fig. 2a). However, find-
ings were highly heterogeneous (I2 = 98.5%; p < 0.001).
Subgroup analysis of studies categorised by the form of
dysglycaemia (T2DM, PCOS and “other”) found that whilst
ZAGwas lower in each category compared to healthy controls
there was high heterogeneity and the results for PCOS provid-
ed the only significant difference (−17.63 [−25.39,
−9.87] mg.L-1).
3.3.2 Overweight and obese data only
Three studies (n = 332), reporting four cohorts, included com-
parisons between individuals with dysglycaemia and a
matched overweight or obese, but metabolically healthy, con-
trol group (Supplementary Materials Section 2: Table 2 and
Fig. 2B). The pooled mean difference between these groups
was not significant (−0.30 [−3.67, 3.07] mg. L−1; I2 = 28.0%;
p = 0.225). Full details of the cohorts included in this restricted
meta-analysis can be found in the Supplementary Materials
(Section 2: Table 2).
3.4 Narrative review
Six out of 10 correlations (nine studies) reported a negative
association between ZAG and FIns, whilst one reported a
positive association. Circulating FG had a significant negative
association with ZAG in four studies and one study reported a
positive association between FG and ZAG. Only two studies
reported a significant negative association with 2 h/RG mea-
sures. Four out of five studies (five out of six cohorts) that
included results for HbA1c reported a significant negative
association. Six studies reported significant negative correla-
tions between ZAG and HOMA-IR, with one reporting a sig-
nificant association. (Supplementary Materials Section 2:
Fig. 3) (39).
4 Discussion
The findings of our meta-analyses and narrative review sug-
gest that increased ZAG is negatively associated with the
development of metabolic dysfunction, particularly that relat-
ed to dysglycaemia. This effect may be mediated by differ-
ences in adiposity, as there were no associations between
ZAG and dysglycaemia in studies where BMI was taken into
account. However, only three studies (encompassing four co-
horts) were included in the latter analysis, which suggests that
further research is needed in this area.
ZAG has been suggested to be an adipokine that acts as a
lipid-mobilising factor playing a role in lipolysis in adipose
tissue (9, 10). Reduction in the levels of ZAG could lead to
lower rates of lipolysis and subsequent accumulation of lipids.
This resulting lipotoxicity is recognised to result in cellular
dysfunction, including impaired glucose uptake and pancreat-
ic beta-cell dysfunction (40, 41) thus increasing the likelihood
of metabolic diseases such as T2DM. The role of lipotoxicity
in T2DM development is also attributed to increased inflam-
mation through changes in cytokine profiles, which extends to
adipokines (42). Therefore, if declining ZAG levels are asso-
ciated with the onset of lipotoxicity, this could suggest a pos-
sible anti-inflammatory role of ZAG, which is supported by its
positive association with adiponectin (13, 14, 31, 43, 44) and
negative association with TNF-alpha (12, 45). Furthermore,
ZAG mRNA expression in both subcutaneous and visceral
adipose tissue is largely found to be predicted by adiponectin
mRNA expression (33).
Along with being modulated by levels of adiposity,
ZAG has also been directly implicated in the metabolic
action of adipose tissue (18). For example, ZAG has been
associated with reduced insulin sensitivity in visceral ad-
ipose tissue, suggesting a feedback loop whereby in-
creased visceral adiposity reduces ZAG expression, which
in turn may increase adverse metabolic functioning of
visceral adipose tissue (31). A potential link been ZAG
and the metabolic activity of visceral adipose tissue is
important given the deleterious impact of visceral fat to
metabolic health (46) and the risk of T2DM. In the oppo-
site direction, higher levels and greater expression of
ZAG have been associated with the browning of adipose
tissue, which could have positive implications to metabol-
ic health (47).
The role of ZAG in adipose tissue metabolism and the
results from this meta-analyses raise the question as to wheth-
er the relationship between ZAG and dysglycaemia is in fact
mediated by, or independent of, adiposity. In contrast to the
findings of this meta-analysis, Yeung and colleagues investi-
gated the difference in ZAG messenger ribonucleic acid
(mRNA) and protein expression in individuals with normal
glucose tolerance and T2DM patients, all of whom were over-
weight or obese. The mRNA expression and protein content
of ZAG in adipose tissuewas found to be 1.5-fold and 2.4-fold
lower in those with T2DM (35), indicating that the relation-
ship between ZAG and dysglycaemia may be independent of
adiposity.
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Treating rats with recombinant human ZAG has also been
shown to decrease circulating levels of glucose and triglycer-
ides, as well as increasing the expression of glucose transport-
er 4 (GLUT4), without a decrease in food or water intake (48).
These findings are consistent with previous observations dem-
onstrating a positive association between subcutaneous ZAG
mRNA and GLUT4 mRNA expression in adipose tissue (32).
However, whether ZAG's mechanistic role in GLUT4 trans-
location is mediated by adiposity independent pathways needs
to be clarified and this may be better understood through
mRNA analysis rather than circulating concentrations.
The magnitude of the influence of adiposity on other
adipokines in MetS and subsequent T2DM also varies in the
literature. Comparison of normal weight, overweight, obese
and morbidly obese T2DM patients with metabolically
healthy normal weight controls showed a difference in
adipokine markers that did not exist in normal weight
T2DM subjects, but the difference was exacerbated by being
overweight or (morbidly) obese (49). Adiponectin, a com-
monly measured anti-inflammatory adipokine, has been
shown to be lower in obese subjects compared to metabolical-
ly healthy normal weight controls, but there was no difference
between obese subjects and T2DM patients (50). A previous
systematic review and meta-analysis on circulating
adiponectin and T2DM did reveal that across 15 prospective
studies (14,598 participants), higher levels of adiponectin
were associated with a lower risk of T2DM (51). With 13 of
these studies stratified for BMI (<25 kg.m-2 and ≥ 25 kg.m-2),
it was found that the relationship remained significant.
As the first study to summarise the literature surrounding
the association between circulating ZAG and dysglycaemia, it
identifies key limitations in the literature. Firstly, substantial
heterogeneity exists, meaning more research is needed to es-
tablish whether ZAG is a valuable biomarker in the develop-
ment of dysglycaemia. Secondly, there is a need to determine
if the alterations in ZAG occur before the onset of
dysglycaemia or vice versa. Furthermore, the summarised da-
ta shows a lack of studies isolating individuals by adiposity
status to further determine if the relationship between ZAG
and dysglycaemia is primarily driven by adiposity, or whether
there are adiposity independent pathways linking ZAG to
dysglycaemia.
This meta-analysis also has important limitations. Mainly,
the inability to undertake a meta-analysis on correlation or
association statistics between ZAG and markers of glucose
control and IR. Additionally, there has been some investiga-
tion into the relationship between other measures of ZAG (i.e.
adipose tissue mRNA and protein content) and dysglycaemia
which warrants investigation.
In conclusion, this is the first study to review the current
findings on circulating concentrations of ZAG and
dysglycaemia. More investigations into changes in circulating
ZAG with the development of dysglycaemia, with the
removal of adiposity as a confounder, are needed to provide
a clearer understanding.
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